Replies to post #13360 on GTC Biotherapeutics (fka GTCB)

[vinmantoo]

<The Ovation deal and the submission will play 2nd fiddle to the cash flow headline IMO. People will begin to recognize a lowered annual cash burn going forward and real revenue possibilities within a few short years.>

That could be the biggest piece of news form this earnings report. We need to see Cox unequivocally state that the burn rate has been significantly cut by the Ovation deal. It seems to me the low trading volume is because everyone is waiting upon these key events, 1) finalization of the Ovation deal, 2) FDA submission, 3) cash burn reduction announcement, 4) the possibility of new cash being raised. The latter would hopefully come from an announcement of another deal with bigger up front money or an announcement of a loan from one of GTCB's partners would be far more welcome than another big dilution at these low prices.